why choose us

First received: October 03, 2024

Clinical Trial: A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Overweight or Obese
Type 2 Diabetes Mellitus (T2DM)

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 W

Brief Summary: This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Read more